EE155 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-17A and IL-12/23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons | Publicación